The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Activation of BRCA1/BRCA2-Associated Helicase BACH1 Is Required for Timely Progression through S Phase
Open accessAbstract
BACH1 (also known as FANCJ and BRIP1) is a DNA helicase that directly interacts with the C-terminal BRCT repeat of the breast cancer susceptibility protein BRCA1. Previous biochemical and functional analyses have suggested a role for the BACH1 homolog in Caenorhabditis elegans during DNA replication. Here, we report the association of BACH1 with a distinct BRCA1/BRCA2-containing complex during the S phase of the cell cycle. Depletion of BACH1 or BRCA1 using small interfering RNAs results in delayed entry into the S phase of the cell cycle. Such timely progression through S phase requires the helicase activity of BACH1. Importantly, cells expressing a dominant negative mutation in BACH1 that results in a defective helicase displayed increased activation of DNA damage checkpoints and genomic instability. BACH1 helicase is silenced during the G(1) phase of the cell cycle and is activated through a dephosphorylation event as cells enter S phase. These results point to a critical role for BACH1 helicase activity not only in the timely progression through the S phase but also in maintaining genomic stability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FANCJ helicase activity induced in S phase is also required for FANCJ to promote S phase progression and possibly intra-S phase checkpoints [71,72].”
From Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1 (2011) · cites this paper as [71]
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
BRCA1 mutations in primary breast and ovarian carcinomas.
Futreal, P., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L., Haugen-Strano, A., Swensen, J., & Miki, Y. (1994) · Science · doi:10.1126/science.7939630 · Cited by 1,378
Brca1 Controls Homology-Directed DNA Repair
Moynahan, M. E., Chiu, J. W., Koller, B. H., & Jasin, M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80202-6 · Cited by 1,245
Méndez, J., & Stillman, B. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8602-8612.2000 · Cited by 925
Schultz, L. B., Chehab, N. H., Malikzay, A., & Halazonetis, T. D. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.7.1381 · Cited by 916
Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage
Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., & Livingston, D. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80503-6 · Cited by 900
The BRCT Domain Is a Phospho-Protein Binding Domain
Yu, X., Chini, C. C. S., He, M., Mer, G., & Chen, J. (2003) · Science · doi:10.1126/science.1088753 · Cited by 862
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
Tavtigian, S. V., Simard, J., Rommens, J. M., Couch, F. J., Shattuck-Eidens, D. M., Neuhausen, S. L., Merajver, S. D., Thorlacius, S., Offit, K., Stoppa‐Lyonnet, D., et al. (1996) · Nature Genetics · doi:10.1038/ng0396-333 · Cited by 838
A superfamily of conserved domains in DNA damage‐ responsive cell cycle checkpoint proteins
Bork, P., Hofmann, K., Bucher, P., Neuwald, A. F., Altschul, S. F., & Koonin, E. V. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.1.9034168 · Cited by 746
RAP80 Targets BRCA1 to Specific Ubiquitin Structures at DNA Damage Sites
Sobhian, B., Shao, G., Lilli, D. R., Culhane, A. C., Moreau, L. A., Xia, B., Livingston, D. M., & Greenberg, R. A. (2007) · Science · doi:10.1126/science.1139516 · Cited by 697
Flagged first, then by citations
Research works printed but not linked: 1
- Lonn U., 1990, Cancer Res, 50, 3141
Cited by
Sorted by citations
Items 101–111 of 111
Rebbeck, T. R., Mitra, N., Domchek, S. M., Wan, F., Chuai, S., Friebel, T. M., Panossian, S., Spurdle, A. B., Chenevix‐Trench, G., Singer, C. F., et al. (2023) · doi:10.1158/0008-5472.c.6499160.v1
Data from Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer
Moyer, C. L., Ivanovich, J. L., Gillespie, J. L., Doberstein, R., Radke, M. R., Richardson, M. E., Kaufmann, S. H., Swisher, E. M., & Goodfellow, P. J. (2023) · doi:10.1158/0008-5472.c.6511902.v1
Data from Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer
Moyer, C. L., Ivanovich, J. L., Gillespie, J. L., Doberstein, R., Radke, M. R., Richardson, M. E., Kaufmann, S. H., Swisher, E. M., & Goodfellow, P. J. (2023) · doi:10.1158/0008-5472.c.6511902
Calvo, J. A., Fritchman, B., Hernandez, D., Persky, N. S., Johannessen, C. M., Piccioni, F., Kelch, B. A., & Cantor, S. B. (2023) · doi:10.1158/1541-7786.c.6545031.v1
Molecular Symphony in Breast Cancer: Insights on Genomic Discoveries and Epigenetic Regulation
Thombre, K. R., Gupta, K. R., & Umekar, M. J. (2025) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/0118756921389643250731042712
The Role of BRCA1 in DNA Double-strand Break Repair
Dever, S. M. (2009) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/f775-c418
Hoyt, J. (2008) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/1x7h-4k63
Guillemette, S. (2014) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2w59b
Metadata
- Authors
- Kumaraswamy, E., & Shiekhattar, R.
- Affiliations
- The Wistar Institute (US)
- ORCID
- Shiekhattar, Ramin
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2007-10-01
- Volume
- 27
- Issue
- 19
- Pages
- 6733-6741
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC2099226
- OpenAlex
- W2138707085
- Cited by
- 110
- References
- 45
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 4 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 6 · 2012: 10
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (CA90758, R01CA090758)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- BACH1, BRCA1, BRCA2, DNA helicase, S phase progression, cell cycle, BRCT domain, DNA damage checkpoint, genomic instability, dephosphorylation, G1 phase, Caenorhabditis elegans, dominant negative mutation
- MeSH terms
- Animals, Chromatin, DNA Damage, Enzyme Activation, Humans, S Phase, Caenorhabditis elegans, BRCA1 Protein, BRCA2 Protein, Tumor Suppressor Proteins, RNA, Small Interfering, Ubiquitin-Protein Ligases, Multiprotein Complexes, Basic-Leucine Zipper Transcription Factors, Fanconi Anemia Complementation Group Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
